MedTrace Logo

Nalbuphine as Adjuvant During Bilateral Suprazygomatic Maxillary Nerve Block for Pediatric Cleft Palate Repair

NCT06100315 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 60

Last updated 2025-02-04

No results posted yet for this study

Summary

The aim of this study is to evaluate the efficacy of adding nalbuphine to bupivacaine via suprazygomatic nerve block for postoperative pain control and emergence agitation management in pediatrics aged from to 1 to 7 years who were maintained on sevoflurane inhalational anesthesia and scheduled for cleft lip and palate operation.

Conditions

  • Complication Following Peripheral Nerve Block

Interventions

DRUG

Nalbuphine

bupivacaine 0.125% of 0.2 ml/kg and 0.1 mg/kg nalbuphine

Sponsors & Collaborators

  • Assiut University

    lead OTHER

Principal Investigators

  • Ekram AA Osman, professor · Assiut University

Eligibility

Min Age
12 Months
Max Age
7 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-07-31
Primary Completion
2026-01-31
Completion
2026-01-31

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06100315 on ClinicalTrials.gov